|  |
| --- |
| **Table S4.** Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) for number of nevi in relation to the risk of breast cancer, stratified by mean UV dose in county of birth, E3N cohort (n=89,802) |
|  | **Mean UV dose in county of birth <1.48 kJ/m²** | **Mean UV dose in county of birth ≥1.48 kJ/m²** |
|  | ***All breast cancers*** |
| **Number of nevi** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** |
| None | 4406 | 320 | 1.00 (Reference) | 4315 | 288 | 1.00 (Reference) |
| A few | 17,517 | 1128 | 1.02 (0.90-1.17) | 17,238 | 1183 | 1.06 (0.92-1.22) |
| Many | 14,811 | 1037 | 0.96 (0.84-1.09) | 15,710 | 1022 | 1.12 (0.98-1.29) |
| Very many | 4185 | 284 | 1.10 (0.94-1.30) | 4170 | 250 | 1.09 (0.92-1.30) |
| Ptrend |  |  | 0.86 |  |  | 0.13 |
|  | ***In situ breast cancers*** |
| **Number of nevi** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** |
| None | 4406 | 35 | 1.00 (Reference) | 4315 | 48 | 1.00 (Reference) |
| A few | 17,517 | 118 | 1.13 (0.75-1.72) | 17,238 | 152 | 1.05 (0.71-1.57) |
| Many | 14,811 | 117 | 0.97 (0.64-1.46) | 15,710 | 127 | 1.12 (0.75-1.66) |
| Very many | 4185 | 28 | 1.15 (0.69-1.90) | 4170 | 30 | 1.36 (0.86-2.16) |
| Ptrend |  |  | 0.83 |  |  | 0.15 |
|  | ***Invasive breast cancers*** |
| **Number of nevi** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** | **n** | **Cases** | **Model 3****Multivariable HRa** **(95% CI)** |
| None | 4406 | 285 | 1.00 (Reference) | 4315 | 240 | 1.00 (Reference) |
| A few | 17,517 | 1010 | 1.01 (0.88-1.16) | 17,238 | 1031 | 1.06 (0.92-1.23) |
| Many | 14,811 | 920 | 0.96 (0.83-1.10) | 15,710 | 895 | 1.13 (0.97-1.30) |
| Very many | 4185 | 256 | 1.10 (0.93-1.30) | 4170 | 220 | 1.05 (0.87-1.26) |
| Ptrend |  |  | 0.79 |  |  | 0.28 |

aAdjusted for education, menopausal status, age at menopause (in postmenopausal women), use of menopausal hormone therapy (in postmenopausal women), use of premenopausal progestagens,personal history of benign breast disease, family history of breast cancer and and stratified according to year of birth in 5-year categories